About Beckley Psytech
Beckley Psytech is a company based in Oxford (United Kingdom) founded in 2019 by Cosmo Feilding Mellen and Lady Amanda Feilding. Beckley Psytech has raised $152.62 million across 4 funding rounds from investors including Bain Capital, ATAI and Integrated. The company has 1 employees as of December 31, 2021. Beckley Psytech has completed 1 acquisition, including Eleusis. Beckley Psytech offers products and services including BPL-003 and Psychedelic Pipeline. Beckley Psytech operates in a competitive market with competitors including ATAI, COMPASS Pathways, MindMed, Cybin and Psylo, among others.
- Headquarter Oxford, United Kingdom
- Employees 1 as on 31 Dec, 2021
- Founders Cosmo Feilding Mellen, Lady Amanda Feilding
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Beckley Psytech Limited
- Date of Incorporation 02 Aug, 2018
- Jurisdiction OXFORD, ENGLAND
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$152.62 M (USD)
in 4 rounds
-
Latest Funding Round
$50 M (USD), Series B
Jan 04, 2024
-
Investors
Bain Capital
& 11 more
-
Employee Count
1
as on Dec 31, 2021
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Beckley Psytech
Beckley Psytech offers a comprehensive portfolio of products and services, including BPL-003 and Psychedelic Pipeline.
Intranasal treatment for rapid relief in mental health disorders.
Compounds for clinical trials targeting depression and substance use.
People of Beckley Psytech
Unlock access to complete
Funding Insights of Beckley Psytech
Beckley Psytech has successfully raised a total of $152.62M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $50 million completed in January 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Beckley Psytech
Beckley Psytech has secured backing from 12 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include Bain Capital, ATAI and Integrated.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Integrated is recognized as a venture fund focused on health transformation.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Investments are focused on alternative medicine for health solutions.
|
Locked | Locked | Locked |
Investor details for Beckley Psytech
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Beckley Psytech
Beckley Psytech has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Eleusis.
Investment portfolio details for Beckley Psytech
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Immunomodulatory and neuroprotective drug candidates are developed for psychiatry needs.
|
Locked | Locked | 2013 | Locked |
Complete acquisition details for Beckley Psytech
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Beckley Psytech
Detailed financials for Beckley Psytech
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Beckley Psytech Comparisons
Peer comparison for Beckley Psytech
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Beckley Psytech
Beckley Psytech operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as ATAI, COMPASS Pathways, MindMed, Cybin and Psylo, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| Locked | Locked | Locked |
Therapies for mental disorders, including psilocybin for depression, are developed.
|
|
| Locked | Locked | Locked |
Psychedelic-based therapies for brain health disorders are developed.
|
|
| Locked | Locked | Locked |
Psychedelic therapeutics for psychiatric disorders are developed and provided.
|
|
| Locked | Locked | Locked |
Psychedelic-derived therapeutics for mental illnesses are developed.
|
Detailed competitors of Beckley Psytech
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Beckley Psytech
Complete news archive for Beckley Psytech
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Beckley Psytech
Beckley Psytech was founded in 2019 and raised its 1st funding round 1 year after it was founded.
Beckley Psytech is headquartered in Oxford, United Kingdom. It is registered at Oxford, Oxfordshire, United Kingdom.
Cosmo Feilding Mellen is the current CEO of Beckley Psytech. They have also founded this company.
Beckley Psytech is a funded company, having raised a total of $152.62M across 4 funding rounds to date.
As of Dec 31, 2021, the latest employee count at Beckley Psytech is 1.
Beckley Psytech was founded in 2019 in Oxford, United Kingdom. Focus is placed on the biotechnology sector, where drugs targeting neurological and psychiatric disorders are developed. Innovative formulations of under-researched psychedelic agents are explored, alongside new chemical entities designed to enhance traditional psychedelics. These treatments address mental health and neurological conditions through clinical research and formulation efforts conducted from the UK base.
Beckley Psytech's top competitors include MindMed, COMPASS Pathways and Psylo.
Beckley Psytech offers BPL-003 and Psychedelic Pipeline.
Beckley Psytech has made 1 acquisition, including Eleusis.
Beckley Psytech has 12 investors. Key investors include Bain Capital, ATAI, Integrated, Prime Movers Lab, and Delphi VC.